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Abstract
Background: We conducted a systematic review and meta-analysis to clarify the risk of early and late cardiotoxicity of 
anthracycline agents in patients treated for breast or ovarian cancer, lymphoma, myeloma or sarcoma.
Methods: Randomized controlled trials were sought using comprehensive searches of electronic databases in June 
2008. Reference lists of retrieved articles were also scanned for additional articles. Outcomes investigated were early or 
late clinical and sub-clinical cardiotoxicity. Trial quality was assessed, and data were pooled through meta-analysis 
where appropriate.
Results: Fifty-five published RCTs were included; the majority were on women with advanced breast cancer. A 
significantly greater risk of clinical cardiotoxicity was found with anthracycline compared with non-anthracycline 
regimens (OR 5.43 95% confidence interval: 2.34, 12.62), anthracycline versus mitoxantrone (OR 2.88 95% confidence 
interval: 1.29, 6.44), and bolus versus continuous anthracycline infusions (OR 4.13 95% confidence interval: 1.75, 9.72). 
Risk of clinical cardiotoxicity was significantly lower with epirubicin versus doxorubicin (OR 0.39 95% confidence 
interval: 0.20, 0.78), liposomal versus non-liposomal doxorubicin (OR 0.18 95% confidence interval: 0.08, 0.38) and with 
a concomitant cardioprotective agent (OR 0.21 95% confidence interval: 0.13, 0.33). No statistical heterogeneity was 
found for these pooled analyses. A similar pattern of results were found for subclinical cardiotoxicity; with risk 
significantly greater with anthracycline containing regimens and bolus administration; and significantly lower risk with 
epirubicin, liposomal doxorubicin versus doxorubicin but not epirubicin, and with concomitant use of a 
cardioprotective agent. Low to moderate statistical heterogeneity was found for two of the five pooled analyses, 
perhaps due to the different criteria used for reduction in Left Ventricular Ejection Fraction. Meta-analyses of any 
cardiotoxicity (clinical and subclinical) showed moderate to high statistical heterogeneity for four of five pooled 
analyses; criteria for any cardiotoxic event differed between studies. Nonetheless the pattern of results was similar to 
those for clinical or subclinical cardiotoxicity described above.
Conclusions: Evidence is not sufficiently robust to support clear evidence-based recommendations on different 
anthracycline treatment regimens, or for routine use of cardiac protective agents or liposomal formulations. There is a 
need to improve cardiac monitoring in oncology trials.
Background
Anthracyclines have been the key component of many
cytotoxic regimens since their introduction in the 1960's
and remain important in the treatment of many adult
malignancies including breast cancer, sarcoma, lym-
phoma, and to a lesser extent, gynaecological cancer. In
childhood cancers, anthracyclines are incorporated in
more than 50% of regimens contributing to the overall
survival rates in excess of 75%. For breast cancer long
term survival is also greater than 70% across Europe [1].
This is certainly at least partly due to the widespread
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after surgery for early breast cancer to reduce the risk of
relapse and death.
For all cancers incidence increases with increasing age,
therefore, increasing numbers of patients may have con-
comitant risk factors for cardiac disease at the time of
diagnosis. In parallel, thresholds for offering treatment,
including cytotoxic chemotherapy are becoming lower
and survival is improving. This has resulted in more long
term cancer survivors, including those who are cured and
those with 'chronic' cancer requiring multiple drug inter-
ventions to control their disease. Longer survival high-
lights the importance of long term treatment related
toxicity. Although paediatric malignancies are rare, the
high cure rates achieved over the last two decades has
highlighted the problems which may be encountered in
adult life with relation to treatment induced late effects
[2-4]. Anthracyclines are the drug class most closely asso-
ciated with acute and late cardiac toxicity [5].
It has been known since the 1970s that anthracycline
treatment is associated with an increased risk of heart
failure, and that this is dependent on cumulative dose and
schedule [6]. While the anti-cancer effects of anthracy-
clines are mediated primarily through inhibition of DNA
synthesis, transcription and replication, they also gener-
ate oxygen-derived free radicals using iron as a co-factor
and the mitochondrial respiratory chain. These free radi-
cals cause direct damage to proteins, lipids and DNA and
most available evidence suggests that myocyte apoptosis
is related to increased oxidative stress caused by these
processes [7]. However, cardiac myocytes do not increase
in overall numbers after the postnatal period. Young
adults have a mean of 8.2 billion myocyte nuclei [8], but
around 52 million (0.6%) are lost each year, resulting in a
35% reduction in myocyte numbers during adult life.
Ventricular wall thickness is maintained by increasing
myocyte volume (110 μm3/year), but nevertheless there is
an overall loss of ventricular mass of 0.9 g/year. With
their very limited capacity for mitosis, any additional loss
of myocytes will result in a permanent reduction in myo-
cyte numbers, an increased reliance on adaptive mecha-
nisms and increasing vulnerability during normal age-
dependent cell loss.
Rationale and aims of the systematic review
Many reviews of cardiotoxicity of chemotherapeutic
agents have been published. However, these tend to have
a very broad scope and cover many different agents and
tend to be opinion pieces which may be biased in their
selection and presentation of study results [5,9-11]. Sev-
eral systematic reviews of the topic area have been pub-
lished. These have a very specific focus on a particular
type of cancer [12] or focus just on children [13,14]. Pre-
vious systematic reviews of anthracyclines and cardiotox-
icity in adults have been conducted [15-17], however,
they have a narrower focus than our review, and do not
include detailed information on how cardiotoxicity out-
comes were defined and measured. In addition, several
relevant studies have since been published. The primary
purpose of this review is to systemically analyze all avail-
able data from RCTs on the cardiac effects of anthracy-
cline treatment for cancer in adults and children. To
critically evaluate the cardiac risks associated with
anthracyclines, and to demonstrate the current gaps in
knowledge. This will facilitate design of future prospec-
tive studies collecting long-term data, and will allow
accurate estimation of the lifetime risks and benefits of
anthracycline treatment. In addition this review may
inform long term surveillance programmes for those
receiving anthracyclines.
Methods
This systematic review was conducted according to a
protocol based on published guidelines [18], available
from the corresponding author upon request, and is
reported according to the recent PRISMA guidelines [19]
(see Additional file 1).
Search strategy
Searches were conducted of Medline, EMBASE and the
Cochrane Library in June 2008 using a combination of
free text and thesaurus terms for individual anthracycline
agents combined with terms for different tumour types,
cardiotoxicity and randomised controlled trials (RCTs)
(see Additional file 2). Additional studies were identified
by screening reference lists of identified studies and
reviews. Abstracts and posters were included only if they
w e r e  r e p o r t e d  i n  s u f f i c i e n t  d e t a i l  t o  e n a b l e  f u l l  d a t a
extraction. Studies published in any language were eligi-
ble. Non-published articles were not sought.
Selection criteria
Adults and children treated with an anthracycline for
breast or ovarian cancer, sarcoma, non-Hodgkin's or
Hodgkin's lymphoma and myeloma. The rationale for
choosing these cancers was that they would be likely to
have long-term survivors, and thus longer follow up on
other important outcomes also. We excluded studies on
participants with leukaemia due to the use of multiple
chemotherapy agents known to cause cardiotoxicity con-
founding interpretation of results, and studies of lung and
gastrointestinal (GI) cancers as they also have confound-
ing factors with treatment coupled with poor long term
outcomes making interpretation of results difficult.
Anthracyclines reviewed were: doxorubicin, epirubicin,
daunorubicin and idarubicin. Mitoxantrone was included
if it was compared with another anthracycline. RCTs
comparing any anthracycline agent with another anthra-
cycline agent in liposomal or non-liposomal formulation,Smith et al. BMC Cancer 2010, 10:337
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or another non-anthracycline containing chemotherapy
regimen were included. If chemotherapy regimens con-
sisted of multiple agents, the treatment arms under com-
parison could only differ in the presence or absence of an
anthracycline or type of anthracycline such that the other
therapies being compared were the same between
groups. Studies comparing an anthracycline in addition
to a cardioprotective agent if compared with an anthracy-
cline on its own were also included. All standard dosing
regimens were included; we excluded high dose regi-
mens. Any treatment duration was considered.
Any cardiotoxicity outcome including clinical and sub-
clinical dysfunction was eligible for inclusion. We
included cardiotoxicity evaluated using symptom check-
lists such as World Health Organisation (WHO) Com-
mon Toxicity Criteria (CTC) or New York Health
Association (NYHA), cardiac function evaluated using
MUGA scans and echocardiography and histological
abnormalities by biopsy reported as Billingham scores.
Both early and late cardiotoxicity were evaluated. We
defined early toxicity as effects incurred during treatment
or up to one year following treatment, and late toxicity as
effects that occurred at least one year after treatment
completion.
Data extraction and outcomes
Two reviewers (LAS and VC) independently assessed
whether individual studies met the inclusion criteria. Dis-
agreements were resolved by discussion with co-authors.
Reviewers were not blinded to the identities of the
authors or institutions of the articles as this has not con-
sistently been shown to affect the process (ref handbook).
Data from each trial report were recorded on a spread-
sheet by one reviewer and checked by a second reviewer.
For cardiotoxicity outcomes we recorded how they were
defined, how they were evaluated, when they occurred
(early or late) and whether they occurred on or off treat-
ment. Where the timeframe for the outcome was not
explicitly reported, we inferred this from average length
of follow up in the trial. We used data for the intention-
to-treat (ITT) population as defined by the authors of
each study.
Appraisal of trial quality
Each study was critically appraised for methodological
quality using recognised criteria [20]. The reported
design and conduct of each study were judged for four
components that may introduce bias: method of genera-
tion of the random allocation, concealment of allocation
at randomisation, blinding of trial participants and inves-
tigators, completeness of treatment and follow-up.
Data synthesis
We categorised outcomes as clinical cardiotoxicity if the
outcome was explicitly reported as congestive heart fail-
ure (CHF), and subclinical if the outcome was reported as
a reduction in left ventricular ejection fraction (LVEF) or
other abnormality in cardiac function determined using a
diagnostic test. For outcomes not explicitly defined e.g.
'cardiotoxic event' we categorised them as a mixture of
both clinical and subclinical. If sufficient data were avail-
able, summary estimates of treatment effects were pro-
duced using meta-analysis for each set of treatment
comparisons. When the outcome was rare in one or more
studies (< 3 events in each treatment arm or < 1% event
rate) a Peto odds ratio (OR) fixed effects model was used
for the meta-analysis which has been show to be the least
biased method, and is a good approximation of the rela-
tive risk (RR) when the outcome is rare [21]. For out-
comes that occurred more frequently, RR estimates were
calculated and pooled using DerSimonian and Laird
methods [22]. The I2 was calculated to report the extent
of heterogeneity detected [23]. The I2 describes the pro-
portion of statistical variability between studies in a
meta-analysis that is greater than would be expected due
to chance. Values in the region of 50% indicate moderate
heterogeneity, and greater than 75% is considered sub-
stantial heterogeneity. Analyses were undertaken using
the Stata V10.0 metan macro.
Results
Searches
Searches of electronic data bases identified 3,480 poten-
tially relevant studies. After screening titles and abstracts,
277 full text reports were obtained and a further 15 stud-
ies were identified from reference lists of retrieved arti-
cles. Of these 292 articles, 55 RCTs met our inclusion
criteria (Figure 1). The 237 articles excluded are listed in
Additional file 3; Table S1.
Characteristics of included studies
We included 55 RCTs reporting the treatment com-
parisons listed below. Four RCTs had three treatment 
groups, therefore, contributed data to more than one 
comparison:
• One anthracycline agent compared with either 
mitoxantrone (15) or a non-anthracycline containing 
chemotherapy regimen (8)
• Anthracycline intermittent/bolus dosing compared 
with continuous infusion (4)
• One anthracycline agent compared with another 
anthracycline (20)
• Anthracycline plus a cardioprotective agent com-
pared with anthracycline alone or with placebo (12)
The majority of the studies were on women with
advanced or metastatic breast cancer. Twenty-one studies
included participants with myeloma, lymphoma, sarcoma
or ovarian cancer, and three studies included a mixture of
tumour types (Additional file 4; T able S2). Most studiesSmith et al. BMC Cancer 2010, 10:337
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specifically excluded patients with existing cardiac dys-
function; nonetheless, some patients had risk factors for
poorer cardiac outcomes. These were mainly due to prior
treatment with an anthracycline or radiotherapy. Nine
studies specifically reported how many participants had
radiotherapy to the chest - none reported if it had been
delivered to the left side of the chest (Additional file 5;
Table S3). Some (n = 22) studies specifically recruited
patients with no prior anthracycline treatment, fewer (n =
11) recruited patients that were treatment naive. These
tended to be the studies on people with lymphoma and
osteosarcoma (Additional file 4; Table S2). Few pediatric
studies (n = 4) met the inclusion criteria as the majority of
cardiotoxicity studies have been performed on children
with acute leukaemia [13].
Quality assessment
The quality of the included trials was variable ranging
from poor to high quality. Common limitations included:
insufficient details to adequately assess fidelity of ran-
domization, lack of blinding of outcome assessors, car-
diotoxicity outcomes only reported in sub-sets of patients
- not the whole randomised sample, and inadequate
assessment and reporting of cardiotoxicity results, partic-
ularly in studies were this was not a primary endpoint.
Definitions used for different cardiotoxicity outcomes
varied from one study to another, the definition used was
not always reported and the time point when outcomes
occurred was not always clear (Additional file 6; Table S4
a-f). In addition, sample sizes were often too small to pro-
vide reliable estimates of relatively rare adverse events
such as CHF and cardiac related death.
One anthracycline compared with either a non-anthracycline 
chemotherapy regimen or mitoxantrone
Eight studies compared an anthracycline with a non-
anthracycline in women with breast cancer [24-27], ovar-
ian cancer [28], children with lymphoma [29,30] and
adults and children with osteosarcoma [31]. Treatment
regimens varied across studies, and doxorubicin, epirubi-
cin or daunomycin were given with other chemotherapy
agents. Cardiotoxicity outcomes occurred early and on
Figure 1 Results of literature search and selection of randomised controlled trials for systematic review.
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treatment [24,27,28]; late and off treatment [26,29,30],
and some may have occurred late and off treatment
[25,31].
Three studies reported the incidence of CHF, and one
study reported discontinuation due to reduction is LVEF.
We made a post-hoc decision to categorise the discontin-
uation due to reduction in LVEF as a clinical cardiotoxic
event due to the implied harm being greater than for a
reduction in LVEF alone (sub-clinical). An anthracycline
containing regimen increased the risk of clinical cardio-
toxicity -OR 5.43 (95% confidence interval (CI): 2.34,
12.62; p < 0.0001; I2 = 0%); and subclinical cardiotoxicity
OR 6.25 (95% CI: 2.58, 15.13; p < 0.0001). For any cardio-
toxic event (clinical and sub-clinical) the pooled result is
highly dependent on the choice of summary statistic; the
Peto OR showed a significant increase in odds of cardio-
toxicity with anthracycline compared with non-anthracy-
cline: 2.27 (95% CI: 1.50, 3.43, p < 0.0001), whereas, the
RR while higher, was not statistically significant, 4.23
(95% CI: 0.93, 19.38; p = 0.08). One possible explanation
for these differences in effects is due to the different defi-
nitions of a cardiotoxic event used in each study giving
rise to substantial heterogeneity, I2 72.0% (Figures 2, 3 and
4).
Meta-analysis of four studies showed cardiac related
deaths, though infrequent, were significantly higher with
an anthracycline OR 4.94 (95% CI: 1.23, 19.87; p = 0.025;
I2 = 19.3%).
Fifteen studies compared an anthracycline with mitox-
a n t r o n e  i n  w o m e n  w i t h  a d v a n c ed  o r  m e t as t a t i c  b r e a s t
cancer [32-42], multiple myeloma [43], non-Hodgkin's
lymphoma [44], Hodgkin's lymphoma and lymphoma
[45,46]. Treatment regimens varied across studies and
doxorubicin or epirubicin were given either as single
agents or with other chemotherapy agents. Cardiotoxicity
outcomes occurred early and on treatment [39,41]; in the
remaining studies it was unclear when the cardiotoxicity
outcomes occurred and may include both early and late
outcomes.
An anthracycline containing regimen increased the risk
of clinical cardiotoxicity OR 2.88 (95% CI: 1.29, 6.44; p =
0.01; I2 = 0%) compared with a chemotherapy regimen
containing mitoxantrone. There was little difference
between the treatment groups for subclinical cardiotoxic-
ity, and for any cardiotoxic event (clinical and sub-clini-
cal): OR 1.09 (95% CI: 0.74, 1.61; p = 0.673; I2 = 10.6%)
and OR 1.31 (0.57, 3.03; p = 0.521; I2 = 0%), respectively.
Cardiac related deaths were reported by only one study in
one patient in the doxorubicin group (Figures 2, 3 and 4).
Anthracycline intermittent/bolus compared with continuous 
infusion
Four RCTs compared bolus with a continuous infusion in
women with advanced or metastatic breast and breast or
ovarian cancer [47,48], and adults with recurrent or met-
astatic soft tissue sarcoma [49,50]. One study included
participants previously treated with an anthracycline
with unspecified cardiac risk factors in 10/25 (40%) and
15/25 (60%) of women in bolus and continuous groups,
respectively [47]. Patients with known cardiac problems
were excluded from the other studies. Duration of contin-
uous infusion schedules were: 6, 48, 72 and 96 hours;
cumulative doses of anthracyclines received are shown in
Additional file 4; Table S2.
C a r d i o t o x i c i t y  o u t c o m e s  r e p o r t e d  i n  t h e  R C T s  a r e
shown in Additional file 6; Table S4. It was not clear when
the outcomes occurred in one study [50], and it is possi-
ble some events could be classified as late as median fol-
low-up was five years; for the other studies outcomes
occurred early and on treatment.
Epirubicin or doxorubicin given as a bolus significantly
increased the risk of clinical cardiotoxicity, OR 4.13 (1.75,
9.72; p = 0.001; I2 = 0%), and subclinical cardiotoxicity OR
3.04 (1.66, 5.58; p < 0.0001; I2 = 65.5%), compared with
continuous infusion (Figures 2, 3 and 4). For subclinical
cardiotoxicity the pooled result was highly dependent on
the choice of summary statistic - random effects RR 1.93
(95% CI: 0.84, 4.44). One possible explanation for the dif-
ference in the effect estimates is the different definition
for LVEF reduction used in each study giving rise to sub-
stantial heterogeneity. Cardiac related deaths were infre-
quent in either treatment group in two studies
(Additional file 6; Table S4).
There were no significant differences in response rates,
remission or survival among patients in each study
according to treatment group.
One anthracycline compared with another
Thirteen studies compared doxorubicin with epirubicin.
The majority of the studies were on women with
advanced or metastatic breast cancer [38,40,51-57], three
were on women with ovarian cancer [28,58,59], and one
studied patients with non-Hodgkin's lymphoma [60].
Some participants had cardiac risk factors at baseline,
mainly due to prior treatment with an anthracycline or
radiotherapy (Additional file 6; Table S4).
Cardiotoxicity outcomes reported in the studies are
shown in Additional file 6; Table S4. Outcomes occurred
early and on treatment in five studies; in the remaining it
was not clear when they occurred and it is possible some
events could be classified as late cardiotoxicity as follow-
up was greater than one year.
Epirubicin significantly decreased the risk of clinical
cardiotoxicity OR 0.39 (0.20, 0.78; p = 0.008; I2 = 0.5%),
subclinical cardiotoxicity OR 0.30 (0.16, 0.57; p < 0.0001;
I2 = 1.7%) and any cardiotoxic event (clinical and sub-
clinical) OR 0.47 (0.31, 0.71; p < 0.0001; I2 = 43.2%) com-
pared with doxorubicin (Figures 2, 3 and 4). Cardiac
related deaths were infrequent in either treatment group.Smith et al. BMC Cancer 2010, 10:337
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Figure 2 Clinical cardiotoxicity defined as incidence of CHF in RCTs comparing different treatment regimens. The open diamond represents 
the pooled Peto Odds Ratio and 95% confidence interval (CI) for each treatment comparison. I-squared represents the proportion of variability be-
tween studies in excess of that expected due to chance, and p = probability that differences between study estimates are due to chance.
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Figure 3 Sub clinical cardiotoxicity defined as reduction LVEF in RCTs comparing different treatment regimens. The open diamond repre-
sents the pooled Peto Odds Ratio and 95% CI for treatment comparisons 1-4, and relative risk (RR) with 95% CI for comparisons 5-7. I-squared repre-
sents the proportion of variability between studies in excess of that expected due to chance, and p = probability that the differences between study 
estimates are due to chance.
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1.20 (0.36, 4.01)
3.04 (1.66, 5.58)
0.38 (0.07, 1.99)
0.13 (0.01, 2.12)
0.16 (0.06, 0.43)
0.38 (0.08, 1.83)
0.72 (0.21, 2.44)
0.30 (0.16, 0.57)
0.47 (0.23, 0.95)
0.23 (0.13, 0.40)
0.29 (0.05, 1.69)
0.30 (0.20, 0.46)
1.17 (0.43, 3.21)
1.17 (0.43, 3.21)
0.27 (0.11, 0.66)
0.34 (0.15, 0.76)
0.27 (0.10, 0.72)
0.30 (0.18, 0.49)
6.25 (2.58, 15.13)
6.25 (2.58, 15.13)
0.66 (0.11, 3.95)
0.26 (0.04, 1.60)
3.90 (0.78, 19.56)
2.97 (0.70, 12.64)
0.70 (0.22, 2.25)
1.63 (0.40, 6.66)
0.46 (0.13, 1.57)
1.44 (0.57, 3.63)
1.12 (0.33, 3.77)
1.06 (0.45, 2.51)
1.09 (0.74, 1.61)
2.13 (0.83, 5.46)
3.47 (0.46, 26.39)
13.79 (4.05, 46.91)
1.20 (0.36, 4.01)
3.04 (1.66, 5.58)
0.38 (0.07, 1.99)
0.13 (0.01, 2.12)
0.16 (0.06, 0.43)
0.38 (0.08, 1.83)
0.72 (0.21, 2.44)
0.30 (0.16, 0.57)
0.47 (0.23, 0.95)
0.23 (0.13, 0.40)
0.29 (0.05, 1.69)
0.30 (0.20, 0.46)
1.17 (0.43, 3.21)
1.17 (0.43, 3.21)
0.27 (0.11, 0.66)
0.34 (0.15, 0.76)
0.27 (0.10, 0.72)
0.30 (0.18, 0.49)
Favours a   Favours b 
1 .01 .1.2 1 510 100
.
.
.
.
5 liposomal doxorubicin (a) v doxorubicin (b) (RR)
Harris 2002
O’Brien 2004
Rifkin 2006
Subtotal  (I-squared = 48.5%, p = 0.143)
6 liposomal doxorubicin (a) v epirubicin (b) (RR)
Chan, 2004
Subtotal  (I-squared = .%, p = .)
7 cardioprotective agent (a) v none (b) (RR)
Lopez, 1998
Marty, 2006
Venturini, 1996
Subtotal  (I-squared = 0.0%, p = 0.785)
0.52 (0.27, 0.97)
0.21 (0.11, 0.40)
0.24 (0.03, 2.15)
0.31 (0.20, 0.48)
1.15 (0.47, 2.84)
1.15 (0.47, 2.84)
0.29 (0.12, 0.74)
0.40 (0.20, 0.82)
0.27 (0.09, 0.79)
0.33 (0.20, 0.55)
0.52 (0.27, 0.97)
0.21 (0.11, 0.40)
0.24 (0.03, 2.15)
0.31 (0.20, 0.48)
1.15 (0.47, 2.84)
1.15 (0.47, 2.84)
0.29 (0.12, 0.74)
0.40 (0.20, 0.82)
0.27 (0.09, 0.79)
0.33 (0.20, 0.55)
Favours a   Favours b 
1 .01 .1.2 1 510 100Smith et al. BMC Cancer 2010, 10:337
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There was no evidence of a difference in tumour response
rate or survival between epirubicin and doxorubicin.
Four studies compared liposomal doxorubicin with
conventional doxorubicin in women with metastatic
breast cancer [61-63], and in men and women with multi-
ple myeloma [64]. In the study of previously untreated
patients with multiple myeloma, cardiac risk factors were
absent. In two of the studies some women had cardiac
dysfunction at baseline and in one, cardiac dysfunction
was absent at baseline, however, risk factors due to prior
Figure 4 Clinical and subclinical cardiotoxicity in RCTs where cardiotoxicity outcomes could not be categorised as one or the other. The 
open diamond represents the pooled Peto Odds Ratio and 95% CI for treatment comparisons 1, 2 and 4, and relative risk (RR) with 95% CI for compar-
isons 5-7. I-squared represents the proportion of variability between studies in excess of that expected due to chance, and p = probability that differ-
ences between study estimates are due to chance.
.
.
.
.
.
.
1 anthracycline (a) v non-anthracycline (b) (OR)
Feher 2005
Hernadi 1988a
Martin 2003
Sweetnam 1986
Subtotal  (I-squared = 72.0%, p = 0.013)
2 anthracycline (a) v mitoxantrone (b) (OR)
Cavo 2002
Pavlovsky 1992
Stewart 1997
Subtotal  (I-squared = 0.0%, p = 0.898)
4 epirubicin (a) v doxorubicin (b) (OR)
Bezwoda 1986
FESG, 1988 
Gasparini 1991
IMBSWE, 1988
Jain 1995
Lawton 1993b
Subtotal  (I-squared = 43.2%, p = 0.117)
5 liposomal doxorubicin (a) v doxorubicin (b) (RR)
Batist 2001
Harris 2002
O’Brien 2004
Subtotal  (I-squared = 0.0%, p = 0.498)
6 liposomal doxorubicin (a) v epirubicin (b) (RR)
Chan, 2004
Subtotal  (I-squared = .%, p = .)
7 cardioprotective agent (a) v none (b) (RR)
Marty, 2006
Speyer, 1992
Swain, 1997
Venturini, 1996
Wexler 1996
Subtotal  (I-squared = 70.9%, p = 0.008)
1.49 (0.91, 2.42)
4.63 (0.24, 90.41)
5.13 (1.64, 16.02)
8.82 (2.87, 27.12)
2.27 (1.50, 3.43)
1.52 (0.54, 4.26)
1.02 (0.20, 5.32)
0.95 (0.06, 15.21)
1.31 (0.57, 3.03)
0.14 (0.01, 1.41)
0.08 (0.02, 0.37)
0.13 (0.00, 6.51)
0.53 (0.33, 0.84)
1.14 (0.30, 4.39)
1.00 (0.06, 16.40)
0.47 (0.31, 0.71)
0.29 (0.15, 0.56)
0.38 (0.20, 0.72)
0.23 (0.13, 0.40)
0.29 (0.20, 0.41)
1.17 (0.43, 3.21)
1.17 (0.43, 3.21)
0.25 (0.12, 0.52)
0.13 (0.06, 0.26)
0.39 (0.26, 0.59)
0.29 (0.12, 0.70)
0.05 (0.01, 0.19)
0.27 (0.20, 0.36)
1.49 (0.91, 2.42)
4.63 (0.24, 90.41)
5.13 (1.64, 16.02)
8.82 (2.87, 27.12)
2.27 (1.50, 3.43)
1.52 (0.54, 4.26)
1.02 (0.20, 5.32)
0.95 (0.06, 15.21)
1.31 (0.57, 3.03)
0.14 (0.01, 1.41)
0.08 (0.02, 0.37)
0.13 (0.00, 6.51)
0.53 (0.33, 0.84)
1.14 (0.30, 4.39)
1.00 (0.06, 16.40)
0.47 (0.31, 0.71)
0.29 (0.15, 0.56)
0.38 (0.20, 0.72)
0.23 (0.13, 0.40)
0.29 (0.20, 0.41)
1.17 (0.43, 3.21)
1.17 (0.43, 3.21)
0.25 (0.12, 0.52)
0.13 (0.06, 0.26)
0.39 (0.26, 0.59)
0.29 (0.12, 0.70)
0.05 (0.01, 0.19)
0.27 (0.20, 0.36)
Favours a   Favours b 
1 .01 .1.2 1 510 100
.
.
.
5 liposomal doxorubicin (a) v doxorubicin (b) (RR)
Batist 2001
Harris 2002
O’Brien 2004
Subtotal  (I-squared = 32.2%, p = 0.229)
6 liposomal doxorubicin (a) v epirubicin (b) (RR)
Chan, 2004
Subtotal  (I-squared = .%, p = .)
7 cardioprotective agent (a) v none (b) (RR)
Marty, 2006
Speyer, 1992
Swain, 1997
Venturini, 1996
Wexler 1996
Subtotal  (I-squared = 44.2%, p = 0.127)
0.30 (0.15, 0.60)
0.44 (0.25, 0.78)
0.21 (0.11, 0.40)
0.30 (0.21, 0.43)
1.15 (0.47, 2.84)
1.15 (0.47, 2.84)
0.32 (0.17, 0.62)
0.16 (0.07, 0.35)
0.46 (0.33, 0.66)
0.32 (0.13, 0.76)
0.25 (0.11, 0.55)
0.34 (0.27, 0.45)
0.30 (0.15, 0.60)
0.44 (0.25, 0.78)
0.21 (0.11, 0.40)
0.30 (0.21, 0.43)
1.15 (0.47, 2.84)
1.15 (0.47, 2.84)
0.32 (0.17, 0.62)
0.16 (0.07, 0.35)
0.46 (0.33, 0.66)
0.32 (0.13, 0.76)
0.25 (0.11, 0.55)
0.34 (0.27, 0.45)
Favours a   Favours b 
1 .01 .1.2 1 510 100Smith et al. BMC Cancer 2010, 10:337
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treatment with chemotherapy and/or radiotherapy were
present in some of the participants (Additional file 5;
Table S3). One study compared liposomal doxorubicin
with epirubicin in women with metastatic breast cancer
[65]. Women had no cardiac dysfunction at baseline;
however risk factors for cardiac dysfunction were present
in some women due to prior radiotherapy to the chest
and prior chemotherapy (Additional file 5; Table S3). The
cardiotoxicity outcomes occurred early and on treatment
(2 studies); in the others it was not clear when they
occurred and it is possible some events could be classified
as late (3 studies).
Liposomal doxorubicin compared with conventional
doxorubicin decreased the risk of clinical cardiotoxicity
OR 0.18 (0.08, 0.38; p < 0.0001; I2 = 0%), subclinical car-
diotoxicity RR 0.31 (0.20, 0.48; p < 0.0001; I2 = 48.5%) and
any cardiotoxic event (clinical and sub-clinical) RR 0.30
(0.21, 0.43; p < 0.0001; I2 = 32.2%). There was little differ-
ence between liposomal doxorubicin and epirubicin for
subclinical cardiotoxicity, and any cardiotoxic event RR
1.15 (0.47, 2.84; p = 0.754); no cases of CHF were
reported in either group (Figure 2, 3 and 4). Cardiac
related deaths were infrequent in any treatment group.
There was no evidence that suggests a difference in
tumour response rate or survival between liposomal dox-
orubicin and doxorubicin, and whilst time to treatment
failure and time to disease progression were significantly
longer with liposomal doxorubicin than with epirubicin
at equimolar concentrations, survival was comparable.
One study each of doxorubicin [66] and epidoxorubicin
[67] compared with idarubicin found little difference in
risk of any cardiotoxic event (clinical and sub-clinical)
with comparable therapeutic efficacy in patients with
non-Hodgkin's lymphoma.
Anthracycline plus a cardioprotective agent compared with 
an anthracycline
Six RCTs evaluated the cardioprotective agent dexrazox-
ane; four on women with advanced breast cancer [68-71],
one on young people aged no more than 25 years with
sarcoma [72], and one with adults with breast cancer or
sarcoma [72,73]. The ratio of dexrazoxane to anthracy-
cline varied between studies from 10:1 to 20:1. Cumula-
tive doses of anthracyclines received were similar
between randomised groups (Additional file 4; Table S2).
Risk factors for cardiotoxicity were present in some par-
ticipants, largely due to prior treatment with either
anthracyclines or radiotherapy to the chest area; none
had cardiac dysfunction at baseline, (Additional file 5;
Table S3). For two of the studies outcomes occurred early
and on treatment; in the other four studies it was not
clear when the outcomes occurred.
Dexrazoxane given either with doxorubicin or epirubi-
cin significantly reduced the risk of clinical cardiotoxicity
OR 0.21 (0.13, 0.33; p < 0.0001; I2 = 0%), subclinical car-
diotoxicity RR 0.33 (0.20, 0.55; p < 0.0001; I2 = 0%) and
any cardiotoxic event (clinical and sub-clinical) RR 0.34
(0.27, 0.45; p < 0.0001; I2 = 44.2%) compared with doxoru-
bicin or epirubicin with no cardioprotective agent. Car-
diac related deaths were infrequent in either treatment
group (Figure 2, 3 and 4). Meta-analysis of two studies
showed no significant difference between groups, OR
0.39 (95% CI: 0.05, 2.76; p = 0.343).
For carvedilol [74], L-cartinine [75], prenylamine [76],
amifostine [77] and acetylcysteine [78] there was only one
RCT for each agent. No significant differences in cardio-
toxic outcomes were detected between treatment groups.
Additional outcomes not suitable for meta-analysis are
shown in (Additional file 6; Table S4.
The potential modifying effect of specific risk factors
for cardiac outcomes at baseline remains an unanswered
question in these RCTs. The presence or absence of spe-
cific risk factors was not consistently reported, and were
not always balanced between treatment arms in the trials,
potentially affecting results. We were unable to investi-
gate the impact of specific risk factors as data were not
reported separately for patients with and without specific
characteristics. Generally there were insufficient studies
in each pooled analyses to conduct meaningful subgroup
analyses of different groups of trials according to the
presence or absence of a specific risk factor such as prior
anthracycline use or radiotherapy treatment.
Discussion
Our analyses demonstrate that anthracyclines increased
the risk of clinical cardiotoxicity by 5.43 fold, subclinical
cardiotoxicity by 6.25 fold, any cardiotoxicity by 2.27 fold
and the risk of cardiac death by 4.94 fold compared with
non-anthracycline regimens. For clinical cardiotoxicity,
the risk was 4.13 fold higher with bolus administration
compared to continuous infusion, and was 61% lower
with epirubicin compared to doxorubicin. The risk was
also 22% lower with liposomal doxorubicin, which allows
a more favourable tumour to normal tissue concentration
ratio. Risk was also 79% lower with the use of the cardio-
protective agent dexrazoxane, which is an iron chelating
agent and is thought to decrease the cardiotoxic effect of
doxorubicin through preventing free radical formation
[79]. These data however do not allow us to comment on
the absolute risks of early or late cardiac events after
anthracyclines from this heterogeneous group of
patients.
Despite an extensive literature search only 55 out of the
292 papers for which full text articles were obtained were
eligible for this review. This reflects the focus of most
oncology research on cause specific outcomes in relation
to cancer, and only acute outcomes in relation to toxicity.
The majority of the 55 included papers were on women
with advanced breast cancer. As many of the risk factorsSmith et al. BMC Cancer 2010, 10:337
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for breast cancer are common to cardiovascular disease,
the fact that breast cancer is numerically the largest
group in this review may bias the results towards overes-
timating the cardiac risks, unless other competing co-
morbidities are fully controlled for. Many patients with
breast cancer had received prior chemotherapy, and only
some patients with sarcoma, lymphoma and paediatric
malignancy were treatment naïve. Within the breast can-
cer population, some patients had cardiac risk factors, of
particular concern; the impact of left sided chest wall
radiotherapy could not be assessed.
The quality of the papers in terms of determining car-
diac outcome was variable and confounded by sample
sizes which are inadequate to accurately estimate rare
outcomes such as cardiotoxicity. Further limitations
included the fact that they were reported only in subsets
of participants in some studies, lack of common defini-
tions for cardiac outcomes, and lack of common monitor-
ing either in terms of modality to assess cardiac outcome
or in terms of timing and duration of monitoring. This
highlights the limitations of CTC reporting from a cardi-
ology perspective.
A previous systematic review of RCTs and cohort stud-
ies in patients aged less than 18 years at cancer diagnosis
has also addressed anthracycline cardiotoxicity [13]. Only
four RCTs were identified, and the same methodological
problems were encountered as in our review. Bryant and
colleagues found dexrazoxane was noted to offset toxic-
ity, but there was no benefit to longer infusion times in
patients receiving moderate doses of anthracyclines.
A large observational study of cardiac complication
rates of women aged 66 to 80 years old receiving adjuvant
anthracyclines using the Surveillance, Epidemiology and
End Results (SEER) database has been conducted [80]. A
total of 43,338 women were identified, of whom 4,712
received adjuvant anthracyclines, and 3,012 women non-
anthracycline containing regimens. For women aged 66 -
70 years at diagnosis, at 10 years post treatment, 29% of
women who had no chemotherapy had been diagnosed
with CHF, compared with 32.5% and 38.4% for women
who received non-anthracycline and anthracycline based
chemotherapy, respectively. The rates were significantly
higher for anthracycline regimens compared with non-
anthracycline chemotherapy -adjusted hazard ratio (HR)
1.26 (95% CI: 1.12, 1.42). For women aged 71 - 80 years at
diagnosis the risk of CHF was not statistically significant
between the three groups, although the cumulative rates
of CHF were higher than in younger women in all three
groups.
The similar rates of CHF in each group may be due to
selection bias in the groups treated with adjuvant chemo-
therapy in this older age group, or reflect a less aggressive
approach in those who did receive such treatment. The
type of anthracycline used was not reported, but a previ-
ous report on a sub-set of the same data suggests that
doxorubicin was used almost exclusively [81]. The results
from our review suggest that these results cannot be
extrapolated to regimens where epirubicin was used, or
to younger women as the SEER data include a sub-set of
older patients who are at higher risk solely due to their
age [82]. However, the data do potentially reflect clinical
practice more closely, in contrast with outcomes for the
highly selected patients generally included in clinical tri-
als.
Recommendations are that the cumulative dose of
anthracycline should not exceed 600 mg/m2 for doxorubi-
cin and 900 mg/m2 for epirubicin. Our data indicate a
lower risk with continuous infusions compared with
bolus dosing, but in practice this would neither allow
dose escalation nor be a practical strategy to minimize
cardiotoxicity in 'at risk' groups.
Other significant predictors of anthracycline associated
cardiac toxicity include: pre-existing cardiovascular dis-
ease such as coronary artery disease, hypertension,
peripheral vascular disease, and emphysema, diabetes,
ethnicity, age [6,80,83,84]. Treatment related factors are
higher cumulative doses of anthracycline, associated
mediastinal radiation therapy and combination chemo-
therapy (trastuzumab, cyclophoshphamide, etoposide,
melphalan, paclitaxel, mitoxantrone, idarubicin)
[6,17,84]. Longer duration of survival is also a risk factor
for cardiac toxicity, emphasising the importance of moni-
toring for long term effects in the growing population of
cancer survivors [84]. This is borne out by paediatric
studies indicating continuous deterioration of cardiac
function for up to 15 - 30 years after treatment [4,85].
This systemic review and previous published studies
have highlighted the potential cardiac sequelae of anthra-
cyclines. As survival and indeed cure rates have
increased, increased focus on lifetime risk of cancer and
its treatment with strategies to limit short- and long-term
toxicity without compromising efficacy is required. This
is especially important in the paediatric, adolescent and
young adult population where there is a long life expec-
tancy. This requires the clinical assessment and investiga-
tion of pre-treatment cardiac risk with monitoring and
proactive treatment of the cardiac effects of cancer treat-
ment to become an essential component, not only of clin-
ical trials, where cardiotoxicity may be an important
secondary endpoint, but also of routine practice. This will
require widespread agreement on cardiac monitoring
techniques, and schedules with clear and appropriate car-
diac endpoints in order to advance knowledge, and pro-
v i d e  o p t i m a l  c a r d i o l o g y  c a r e  o f  o n c o l o g y  p a t i e n t s .
Changes are necessary in trial protocols and in clinical
practice. In particular:
• The CTC require revision to align them with mod-
ern cardiology evidence and practice.Smith et al. BMC Cancer 2010, 10:337
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• Cardiac function should be measured, and risk fac-
tors for cardiac dysfunction addressed prior to cancer 
treatment with cardiac toxic medication such as 
anthracyclines.
• Markers of cardiac damage and repeat measure-
ments of cardiac function should be undertaken at 
intervals appropriate to the regimen prescribed.
• Cardiac follow-up should be continued long enough 
to accurately define the risk of long-term toxicity. Pri-
mary care colleagues should be alerted to the risks of 
cardiotoxicity in their patients, and if identified 
encouraged to inform the oncologist. This should be 
complimented by regular audit. Only then will it be 
possible to accurately define the competing life-time 
risks of cancer and its treatment which is essential to 
determine the optimal regimen for an individual 
patient, especially when given in the adjuvant setting.
Currently, cardiac monitoring primarily comprises
measurement of LVEF with imaging techniques which
have inherent limitations of inter-observer and inter-
institution variation and of the late manifestation of ven-
tricular dysfunction in the development of cardiac toxic-
ity. The role of markers of cardiac damage or wall stress,
such as cardiac troponins and natriuretic peptides, in
predicting late cardiac effects and guiding treatment is
being actively investigated in prospective research.
Conclusions
Unfortunately, published data are not sufficiently robust
to support clear evidence-based recommendations on
different schedules of anthracyclines, or the routine use
of cardiac protective agents or liposomal preparations in
patients defined as at high risk for anthracycline cardio-
toxicity, such as patients with known cardiac impairment
and/or previous anthracycline exposure. Nonetheless,
these approaches may have a role. An alternative strategy
would be to avoid the use of anthracyclines in favour of
newer cytotoxic drugs with equivalent efficacy, but a
lower risk of cardiac effects. In breast cancer treatment
this might be achieved by moving to taxane-based regi-
mens which appear to have less cardiotoxicity in clinical
trials. Currently, most taxane regimens also contain
anthracyclines given either concurrently or sequentially,
and further RCTs will be required to determine whether
anthracyclines can be omitted without compromising
efficacy, and that the anticipated reduction in late cardiac
and other long-term adverse effects is observed.
Although many risk factors for coronary artery disease
are known, and some of these overlap with risk factors for
anthracycline induced cardiotoxicity, much less is known
about pharmacogenomic risk factors which are impor-
tant in the pathogenesis of many drug side effects includ-
ing those of anthracyclines [86]). This is a potentially
important area for research. The cardiac effects of cancer
treatment usually occur too late to allow dose-adjustment
between cycles of chemotherapy, but if patients' individ-
ual susceptibilities could be defined in advance of chemo-
therapy, then prospective modification of regimens could
be  m a de  no t only  t o r edu c e  a n t hr a cy c line  e x pos ur e in
h i g h  r i s k  i n d i v i d u a l s ,  b u t  a l s o  p o s s i b l y  t o  s a f e l y  a l l o w
higher exposure in individuals at low risk of toxicity.
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